These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 32133742)

  • 1. Targeting USP1-dependent KDM4A protein stability as a potential prostate cancer therapy.
    Cui SZ; Lei ZY; Guan TP; Fan LL; Li YQ; Geng XY; Fu DX; Jiang HW; Xu SH
    Cancer Sci; 2020 May; 111(5):1567-1581. PubMed ID: 32133742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting KDM4A-AS1 represses AR/AR-Vs deubiquitination and enhances enzalutamide response in CRPC.
    Zhang B; Zhang M; Yang Y; Li Q; Yu J; Zhu S; Niu Y; Shang Z
    Oncogene; 2022 Jan; 41(3):387-399. PubMed ID: 34759344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of c-Myc expression by the histone demethylase JMJD1A is essential for prostate cancer cell growth and survival.
    Fan L; Peng G; Sahgal N; Fazli L; Gleave M; Zhang Y; Hussain A; Qi J
    Oncogene; 2016 May; 35(19):2441-52. PubMed ID: 26279298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KDM4B and KDM4A promote endometrial cancer progression by regulating androgen receptor, c-myc, and p27kip1.
    Qiu MT; Fan Q; Zhu Z; Kwan SY; Chen L; Chen JH; Ying ZL; Zhou Y; Gu W; Wang LH; Cheng WW; Zeng J; Wan XP; Mok SC; Wong KK; Bao W
    Oncotarget; 2015 Oct; 6(31):31702-20. PubMed ID: 26397136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ETS transcription factor ERG cooperates with histone demethylase KDM4A.
    Kim TD; Shin S; Janknecht R
    Oncol Rep; 2016 Jun; 35(6):3679-88. PubMed ID: 27109047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer.
    Ponnusamy S; He Y; Hwang DJ; Thiyagarajan T; Houtman R; Bocharova V; Sumpter BG; Fernandez E; Johnson D; Du Z; Pfeffer LM; Getzenberg RH; McEwan IJ; Miller DD; Narayanan R
    Clin Cancer Res; 2019 Nov; 25(22):6764-6780. PubMed ID: 31481513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-10a functions as a tumor suppressor in prostate cancer via targeting KDM4A.
    Mu H; Xiang L; Li S; Rao D; Wang S; Yu K
    J Cell Biochem; 2019 Apr; 120(4):4987-4997. PubMed ID: 30302800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new role of GRP75-USP1-SIX1 protein complex in driving prostate cancer progression and castration resistance.
    Liao Y; Liu Y; Shao Z; Xia X; Deng Y; Cai J; Yao L; He J; Yu C; Hu T; Sun W; Liu F; Tang D; Liu J; Huang H
    Oncogene; 2021 Jun; 40(25):4291-4306. PubMed ID: 34079090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1.
    Kim TD; Jin F; Shin S; Oh S; Lightfoot SA; Grande JP; Johnson AJ; van Deursen JM; Wren JD; Janknecht R
    J Clin Invest; 2016 Feb; 126(2):706-20. PubMed ID: 26731476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SCF(FBXO22) regulates histone H3 lysine 9 and 36 methylation levels by targeting histone demethylase KDM4A for ubiquitin-mediated proteasomal degradation.
    Tan MK; Lim HJ; Harper JW
    Mol Cell Biol; 2011 Sep; 31(18):3687-99. PubMed ID: 21768309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological and genetic targeting of 5-lipoxygenase interrupts c-Myc oncogenic signaling and kills enzalutamide-resistant prostate cancer cells via apoptosis.
    Monga J; Subramani D; Bharathan A; Ghosh J
    Sci Rep; 2020 Apr; 10(1):6649. PubMed ID: 32313135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy.
    Wang J; Wang H; Wang LY; Cai D; Duan Z; Zhang Y; Chen P; Zou JX; Xu J; Chen X; Kung HJ; Chen HW
    Cell Death Differ; 2016 Nov; 23(11):1886-1896. PubMed ID: 27612013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the KDM4B-AR-c-Myc axis promotes sensitivity to androgen receptor-targeted therapy in advanced prostate cancer.
    Tang DE; Dai Y; He JX; Lin LW; Leng QX; Geng XY; Fu DX; Jiang HW; Xu SH
    J Pathol; 2020 Oct; 252(2):101-113. PubMed ID: 32617978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. USP1 (ubiquitin specific peptidase 1) targets ULK1 and regulates its cellular compartmentalization and autophagy.
    Raimondi M; Cesselli D; Di Loreto C; La Marra F; Schneider C; Demarchi F
    Autophagy; 2019 Apr; 15(4):613-630. PubMed ID: 30335599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone demethylase KDM4A plays an oncogenic role in nasopharyngeal carcinoma by promoting cell migration and invasion.
    Zhao J; Li B; Ren Y; Liang T; Wang J; Zhai S; Zhang X; Zhou P; Zhang X; Pan Y; Gao F; Zhang S; Li L; Yang Y; Deng X; Li X; Chen L; Yang D; Zheng Y
    Exp Mol Med; 2021 Aug; 53(8):1207-1217. PubMed ID: 34385569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer.
    Liu C; Yang JC; Armstrong CM; Lou W; Liu L; Qiu X; Zou B; Lombard AP; D'Abronzo LS; Evans CP; Gao AC
    Mol Cancer Ther; 2019 Oct; 18(10):1875-1886. PubMed ID: 31308078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The histone demethylase KDM3A regulates the transcriptional program of the androgen receptor in prostate cancer cells.
    Wilson S; Fan L; Sahgal N; Qi J; Filipp FV
    Oncotarget; 2017 May; 8(18):30328-30343. PubMed ID: 28416760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM).
    Lapidot M; Case AE; Weisberg EL; Meng C; Walker SR; Garg S; Ni W; Podar K; Hung YP; Carrasco RD; Knott A; Gokhale PC; Sharma S; Pozhitkov A; Kulkarni P; Frank DA; Salgia R; Griffin JD; Saladi SV; Bueno R; Sattler M
    Br J Cancer; 2021 Aug; 125(4):582-592. PubMed ID: 34088988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. USP1-mediated deubiquitination of KDM1A promotes the malignant progression of triple-negative breast cancer.
    Su Y; Du Y; He W
    J Biochem Mol Toxicol; 2024 Oct; 38(10):e23864. PubMed ID: 39318028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KIF15-Mediated Stabilization of AR and AR-V7 Contributes to Enzalutamide Resistance in Prostate Cancer.
    Gao L; Zhang W; Zhang J; Liu J; Sun F; Liu H; Hu J; Wang X; Wang X; Su P; Chen S; Qu S; Shi B; Xiong X; Chen W; Dong X; Han B
    Cancer Res; 2021 Feb; 81(4):1026-1039. PubMed ID: 33277366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.